Pune-based Serum Institute of India (SII) is prepared to increase production of injectable poliomyelitis vaccine (IPV) to fill the gap left by France's Sanofi closing its manufacturing plants in India. SII currently supplies half of the 20 million IPV doses to the government's immunization program and can provide additional doses with a 3-4 month notice. Adar Poonawalla, SII CEO, stated that supplying IPV to the government at current prices is unviable for most companies, but SII continues to do so as a service to the nation.
